Clinical Trials Browser

OTHER × Central Nervous System Neoplasms × durvalumab × Clear all

NCT02793466 2023-09-22

Durvalumab in Pediatric and Adolescent Patients

Phase 1 Completed

Lymphoma, Central Nervous System Neoplasms